|
業務類別
|
Biotechnology |
|
業務概覽
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment. |
| 公司地址
| 170 Park Avenue, Florham Park, NJ, USA, 07932 |
| 電話號碼
| +1 908 768-2170 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.celularity.com |
| 員工數量
| 123 |
| Dr. Robert J. Hariri, M.D.,PhD |
Chief Executive Officer and Chairman of the Board |
美元 179.14K |
07/11/2025 |
| Mr. John Sprague |
Acting Chief Financial Officer |
-- |
05/03/2026 |
| Mr. John R. Haines |
Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary |
美元 434.38K |
21/04/2026 |
|
|
| Mr. Vincent LeVien |
Director |
06/06/2025 |
| Ms. Diane L. Parks, M.B.A. |
Independent Director |
07/11/2025 |
| Dr. Peter H. Diamandis, M.D. |
Independent Director |
07/11/2025 |
| Dr. Robert J. Hariri, M.D.,PhD |
Chief Executive Officer and Chairman of the Board |
07/11/2025 |
| Dr. Geoffrey Shiu Fei Ling, M.D. |
Independent Director |
07/11/2025 |
|
|
|
|
